About us

Roivant is a global healthcare company. Our aim is to accelerate the delivery of new medicines to patients.

How Our Model Works


Instead of building our own laboratories, we identify promising medicines in the pipelines of other companies and research institutions that have been de-prioritized due to strategic or financial constraints. We then craft ‘win-win’ arrangements to acquire those candidates, and initiate clinical and nonclinical studies at record pace.

We form a new company, hire an experienced leadership team, and execute on clinical and commercial plans for in-licensed drugs. While each Vant has its own focus and independent leadership, all share a common culture and mission-oriented approach to drug development.

Roivant offers regulatory guidance, manufacturing assistance, digital innovation strategies, nonclinical and Phase 1 study operations, and other functions as needed. The Vants receive the resources of a large-scale organization, while still remaining nimble and entrepreneurial.

We work together to find creative new methods of commercialization that maximize access for patients and offer value to the entire healthcare system.

Who We Are Today

Roivant was founded in May 2014. Today we have a team of several hundred staff members, a strong capital base, and a pipeline of 14 drugs across our family of companies. At present our wholly- or majority-owned subsidiary companies include Axovant, Dermavant, Enzyvant, Myovant, Urovant, and Datavant. And we’re just getting started.

Where We're Heading

We believe that over time the pharmaceutical industry will converge with the healthcare system at large. Roivant intends to be a leader in catalyzing that convergence.

While preserving our commitment to drug development, we are also pursuing opportunities involving new applications of healthcare data, innovative approaches to commercialization, and other means of delivering real value to patients, payers, and the healthcare system as a whole.

Stay tuned.